FindTrial
Sign In

ABT-126

DRUG14 trials

Sponsors

Abbott, AbbVie (prior sponsor, Abbott), AbbVie

Conditions

Alzheimer's DiseaseCognitive Deficits in SchizophreniaHealthyHealthy VolunteersSchizophrenia

Phase 1

A Safety and Tolerability Study of ABT-126 in Elderly
CompletedNCT00867399
AbbottAlzheimer's Disease
Start: 2009-03-31Updated: 2010-11-02
Pharmacokinetic and Exploratory Biomarker Study of ABT-126 in Healthy Volunteers
CompletedNCT00912431
AbbottHealthy
Start: 2009-06-30Updated: 2010-11-02
Pharmacokinetic Study of ABT-126 in Healthy Volunteers
CompletedNCT00959634
AbbottHealthy Volunteers
Start: 2009-08-31Updated: 2010-11-03
Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia
CompletedNCT01043458
AbbottSchizophrenia
Start: 2009-11-30Updated: 2010-11-02
A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease
CompletedNCT01482845
AbbottAlzheimer's Disease
Start: 2011-11-30End: 2012-03-31Updated: 2012-05-02

Phase 2

Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease
CompletedNCT00948909
AbbVie (prior sponsor, Abbott)Alzheimer's Disease
Start: 2009-10-31End: 2010-11-30Updated: 2013-01-31
Safety and Efficacy Study for Cognitive Deficits in Adult Subjects With Schizophrenia
CompletedNCT01095562
AbbVie (prior sponsor, Abbott)Cognitive Deficits in Schizophrenia
Start: 2010-03-31End: 2011-09-30Updated: 2018-06-06
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease
CompletedNCT01527916
AbbVie (prior sponsor, Abbott)Alzheimer's Disease
Start: 2012-02-29End: 2013-11-30Updated: 2014-11-19
Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
CompletedNCT01549834
AbbVie (prior sponsor, Abbott)Alzheimer's Disease
Start: 2012-03-31End: 2013-10-31Updated: 2014-10-31
A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
CompletedNCT01655680
AbbVie (prior sponsor, Abbott)Schizophrenia
Start: 2012-05-31End: 2014-07-31Updated: 2021-07-07
This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
TerminatedNCT01676935
AbbVie (prior sponsor, Abbott)Alzheimer's Disease
Start: 2012-08-31End: 2014-03-31Updated: 2021-08-02
A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia
CompletedNCT01678755
AbbVie (prior sponsor, Abbott)Schizophrenia
Start: 2012-08-31End: 2014-03-31Updated: 2021-07-07
Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease
TerminatedNCT01690195
AbbVie (prior sponsor, Abbott)Alzheimer's Disease
Start: 2012-09-30End: 2014-02-28Updated: 2021-08-02
Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)
TerminatedNCT01834638
AbbVieSchizophrenia
Start: 2013-03-31End: 2014-11-30Updated: 2018-05-02

Related Papers

Efficacy and Safety of the α7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia
The Journal of Clinical Psychiatry2017-09-0815 citations
Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia
JMIR mhealth and uhealth2017-02-21160 citations
ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
2016-10-1831 citations
The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study.
2016-06-2028 citations
Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
2016-01-0127 citations
A phase 2 randomized, controlled trial of the α7 agonist ABT‐126 in mild‐to‐moderate Alzheimer's dementia
Alzheimer s & Dementia Translational Research & Clinical Interventions2015-06-0139 citations